Citigroup’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Citigroup’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,000	Closed	–	–	7506
2016 Q3	$0	Hold	1,000	–	–	﹤0.01%	7326
2016 Q2	$0	Sell	1,000 -2,000	-67%	-$761	﹤0.01%	7765
2016 Q1	$1K	Buy	3,000 +840	+39%	+$346	﹤0.01%	7392
2015 Q4	$1K	Hold	2,160	–	–	﹤0.01%	7484
2015 Q3	$1K	Sell	2,160 -800	-27%	-$410	﹤0.01%	7303
2015 Q2	$1K	Buy	2,960 +300	+11%	+$245	﹤0.01%	7430
2015 Q1	$2K	Hold	2,660	–	–	﹤0.01%	6990
2014 Q4	$2K	Hold	2,660	–	–	﹤0.01%	6908
2014 Q3	$3K	Hold	2,660	–	–	﹤0.01%	6764
2014 Q2	$2K	Buy	+2,660	New	+$3.19K	﹤0.01%	6839

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Citigroup's PVCT Position: Q4 2016 in Review

Citigroup sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 1,000 shares.

Citigroup first reported a position in PVCT in Q2 2014 and held it in 10 quarters. The position peaked at $3K in Q3 2014. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

Citigroup reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
Citigroup sold 1,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016.
Citigroup first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 10 quarters.
Citigroup's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $3K in Q3 2014.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.